Key result
Omega-3 fatty acids administered at 4 g daily for 12 weeks significantly reduced small dense LDL proportions by 11% and decreased apolipoprotein B levels in type 2 diabetic patients.
Why the study?
Does omega-3 fatty acids improve plasma sdLDL, adiponectin, apoB100, and B48 in type 2 diabetic patients with hypertriglyceridemia?
Population
28 type 2 diabetic patients with hypertriglyceridemia
Comparison
Omega-3 fatty acids 4 g daily for 12 weeks vs Placebo 4 g daily for 12 weeks
Design
RCT, randomized, placebo-controlled, double-blind
Follow-up
12 weeks
Authors
Loading...
Supports high-dose omega-3 in T2DM with hypertriglyceridemia; extends RCT evidence on sdLDL/apoB reduction while advising glycemic monitoring.
RCT (n=28)
Double-blind
Randomized
Yes
Does omega-3 fatty acids improve plasma sdLDL, adiponectin, apoB100, and B48 in type 2 diabetic patients with hypertriglyceridemia?
Absolute Event Rate: 32.29% vs 37%
p-value: p=0.001
High-dose omega-3 fatty acid supplementation reduces atherogenic sdLDL and apolipoprotein B levels in type 2 diabetic patients with hypertriglyceridemia, though it may increase fasting blood glucose.
Jun et al. (2011) conducted an RCT in Type 2 Diabetes with Hypertriglyceridemia (n=28). Omega-3 fatty acids vs. Placebo was evaluated on Small dense LDL (sdLDL) proportion (p=0.001). Omega-3 fatty acids administered at 4 g daily for 12 weeks significantly reduced small dense LDL proportions by 11% and decreased apolipoprotein B levels in type 2 diabetic patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: